Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan with concurrent radiotherapy for NSCLC brain metastases (Phase II)
ChiCTR2600121977Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Hainan Medical University
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Second Affiliated Hospital of Hainan Medical University. Primary endpoints: Incidence and severity of adverse events, Treatment-related deaths and 2 more. Started Apr 2026; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR2600121977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121977.